One-step diabetes cure

We seem to be in the midst of a boom era for innovative Type 1 diabetes treatments (for mice at least).

Hope for diabetics

Previously we had commented on Doug Melton’s in vivo reprogramming of adult pancreatic cells into insulin-producing beta cells using a three gene approach.

Now an international group of scientists have been able to induce beta cell formation in vivo with transfer of a single gene (Pax4).  The new method stimulated bystander cells in the pancreas (alpha cells, delta cells, PP cells) to develop into insulin-producing beta cells.

Why is this important?

Lack of beta cells is the key problem in Type 1 diabetes – when the cells are missing the body cannot regulate blood sugar which in turn creates a host of serious complications.

Type 1 diabetics are forced to frequently measure their blood glucose levels and self-inject insulin to avoid dire health consequences.  Beta cell transfer from cadavers (Edmonton Protocol) allows diabetics to escape from the rigors of disease management for a year or more, but they need to take powerful immunosupprressive drugs instead.  In addition, there is a serious shortage of donor cells for transplant.

The ideal approach would seem to be to create new patient-specific beta cells inside the body which would restore normalcy.  The current method brings that promise closer than before.  However, there are some important caveats we should bear in mind:

• these finding are all from a mouse system – humans and mice are not the same and there is no guarantee that the findings will translate
• the gene transfer was applied to embryos – it is unknown whether the same approach would work with more mature subjects
• gene transfer has been a major problem in the past

Having said that, our understanding of diabetes and the biology of the beta cells has never been greater.  Stay tuned for more exciting news!

Related Blogs

 

Preventing type two diabetes
We’ve had several blogs on the topic of prevention of type two diabetes (T2D) over the past few years (see Want to live longer,  Want to live (even) longer and How to avoid diabetes).  The re

MaRS Future of Medicine 2009: Home run for Ontario life sciences
Last week, we held the inaugural MaRS Future of Medicine conference here at the MaRS Centre in Toronto. This major partnering event attracted over 170 attendees including representatives from the maj

BIO Japan 2009
[excerpt align="alignright" width="240" caption=""][/excerpt]if you are developing bio-pharmaceutical products you cannot ignore Japan. The nation is open to partnering and has the resources to speed

Breakthrough: Cellular alchemy and curing diabetes
A finding from Harvard heralds the possibility of a new and unexpected approach for treating diabetes as well as a fundamental shift in the regenerative medicine industry. John McCulloch tells us mor

MaRS Future of Medicine™ 2011: Highlighting the path from discovery to market
From the latest discoveries in neuroscience, to news from Canadian commercialization giants, we peered into the future of medicine in Ontario and found that it looks very positive. The MaRS Future of

Ontario start-ups find success at BioPartnering Europe 2011
Innovative Ontario start-ups extended their global reach last month, generating some promising leads for financing and licensing deals at the 2011 BioPartnering Europe conference. The good news made t

Tags: advisors, diabetes, John McCulloch, life sciences